BioCentury
ARTICLE | Product Development

Somatogen finally completes Phase Ib

August 9, 1993 7:00 AM UTC

Just eight days after filing for a $40 million convertible exchangeable preferred stock offering, Somatogen Inc. announced that it had completed its Phase Ib study of rHb1.1 recombinant hemoglobin in healthy volunteers.

In an industry where investor perceptions of companies can be quixotic, SMTG might have waited until the trial was completed before announcing the offering, thus reassuring investors who have worried that Phase I studies have dragged on for a year and a half. ...